Home › All Companies › BNTC › Quarterly Report

Benitec Biopharma Inc. (BNTC) — Quarterly Report

AI-Powered SEC Filing Analysis

← All BNTC filings
Latest Quarterly Report Filed: 2026-05-14

Key Insights

  • The filing appears to be a 10-Q for Q3 2026 (period ending June 30, 2026), indicating Benitec Biopharma is progressing through its fiscal year with ongoing operational activities across multiple subsidiaries including RNAi Therapeutics Inc, Tacere Therapeutics Inc, and Benitec Limited.
  • The company has multiple equity instruments outstanding including common stock, pre-funded warrants, employee stock options, and various warrant series, suggesting a complex capital structure typical of biotech firms that have utilized multiple financing rounds to fund R&D operations.
  • Significant institutional involvement is indicated by references to Suvreta Capital and multiple underwriting/sales agreements dated through 2025-2026, reflecting recent capital raises that should support near-term operations and development activities.
  • The filing shows substantive R&D and G&A expense tracking across multiple periods and entities, indicating active gene therapy pipeline development, though the truncated content prevents assessment of revenue generation or profitability metrics.
Sentiment: Neutral Significance: 4/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-05-14. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Quarterly Report filings

Filed: 2026-02-12
  • The company reported a decline in research and development expenses in the current quarter compared to the prior year period, which could signal a shift in strategic priorities or cost-cutting measures.
  • The company raised additional capital through the sale of common stock and warrants, potentially to fund ongoing operations and future growth initiatives.
  • The company's accumulated other comprehensive income, which includes items such as foreign currency translation adjustments, has been fluctuating over the past few reporting periods, indicating potential exposure to currency risk or other market factors.
Sentiment: Neutral Significance: 5/10
View Original Filing →

Other reports for Benitec Biopharma Inc.

Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.